NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)

NCT01863693

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Ovarian Cancer

Countries: United Kingdom

This multicenter, prospective, observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with chemotherapy as first-line treatment in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in routine clinical practice. Eligible patients will be followed for approximately 15 months.

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Adult patients, \>/= 18 years of age
* Advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube or primary peritoneal cancer not previously treated with chemotherapy
* Initiating Avastin in combination with chemotherapy

Exclusion Criteria:

* Contraindications, warnings and precautions for use as specified in the Avastin Summary of Product Characteristics

Locations (30)

Bath, United Kingdom
Birmingham, United Kingdom
Bradford, United Kingdom
Bristol, United Kingdom
Burton-on-Trent, United Kingdom
Colchester, United Kingdom
Eastbourne, United Kingdom
Exeter, United Kingdom
Guildford, United Kingdom
Ipswich, United Kingdom
Keighley, United Kingdom
Leeds, United Kingdom
London, United Kingdom
Maidstone, United Kingdom
Manchester, United Kingdom
Metropolitan Borough of Wirral, United Kingdom
Middlesbrough, United Kingdom
Middlesex, United Kingdom
Newport, United Kingdom
Nottingham, United Kingdom
Portsmouth, United Kingdom
Sheffield, United Kingdom
Southampton, United Kingdom
Stoke-on-Trent, United Kingdom
Sutton, United Kingdom
Swansea, United Kingdom
Torquay, United Kingdom
Truro, United Kingdom
Wolverhampton, United Kingdom
York, United Kingdom